Project Grant HT9425261E265
Award Date 7/1/26
Completion Date 6/30/29
Dollars Obligated $637K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Tacoma, WA 98402, USA
Similar Awards
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded The Geneva Foundation a $559,224 project grant effective May 15, 2026, through the Military Medical Research and Development program (CFDA 12.420) to conduct research on "In Vivo Selection of Prometastatic Tumor Microbiota in Pancreatic Cancer." The three-year research initiative, scheduled for completion by May 14, 2029, will be performed at The Geneva Foundation's facility in Tacoma, Washington. This project...
- Federal Grant Award Summary The Geneva Foundation received a $1,009,750 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) awarded August 1, 2025, for a three-year performance period ending July 31, 2028. The award supports genomic and functional characterization of chemoresistance in small cell lung cancer, a research initiative conducted at the foundation's facility in Tacoma, Washington. This project contributes to...
- Federal Project Grant Award Summary The Geneva Foundation received a $909,510 Project Grant awarded May 1, 2025, by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to support precision therapy research for the eradication of brain metastatic breast cancer. The three-year award, with an ultimate completion date of April 30, 2028, will be performed at the foundation's Tacoma, Washington facility. This research initiative aligns with the...
- Federal Project Grant Award Summary The Geneva Foundation received a $487,800 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), effective October 1, 2025 through September 30, 2027. The award funds research to define the cellular origins and molecular vulnerabilities of Notch-driven lymphomas. This research initiative contributes to the Defense Health Agency's broader mission of transforming healthcare for service members...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded The Geneva Foundation a $747,394 project grant effective April 1, 2026, through March 31, 2029, under the Military Medical Research and Development program (CFDA 12.420). The grant supports research and development of antagonism-enforced braking system chimeric antigen receptor T-cell (CAR T-cell) therapeutics for the treatment of TP53-mutant breast cancer. This project represents a targeted advancement in cancer...
- Grant Award Summary The Geneva Foundation received a $999,766 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2026 through August 31, 2029. The award funds research to accelerate personalized T-cell receptor (TCR) immunotherapy for microsatellite-stable colorectal cancer through development of a multimodal prediction model. This research initiative represents the Defense Health Agency's investment...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded The Geneva Foundation a $575,968 Project Grant effective September 30, 2025, under the Military Medical Research and Development program (CFDA 12.420) to conduct an efficacy and feasibility trial of a portable near-infrared hematoma imager for detection of intracranial hemorrhage in acute care settings. The two-year research initiative, concluding September 29, 2027, will be performed in Tacoma, Washington, and focuses...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded The Geneva Foundation a $4.4 million project grant under the Military Medical Research and Development program (CFDA 12.420) to conduct research on extracorporeal immunomodulation to reduce inflammation after severe burns, inhalation injury, and septicemia. The three-year award, obligated on November 1, 2025, with completion targeted for October 31, 2028, will be performed in Tacoma, Washington. The research initiative...
- Federal Project Grant Award Summary The Geneva Foundation received a $4.82 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) awarded July 15, 2025, with a completion date of July 14, 2028. The award funds the development of a patient-matched segmental defect implant system with mechanobiologic activation and antimicrobial coating designed to treat severe fractures. This research initiative represents an...
- Summary The Defense Health Agency awarded The Geneva Foundation a $488,276 project grant under the Military Medical Research and Development program (CFDA 12.420) effective April 1, 2026 through March 31, 2029. The grant funds research and development of an antagonism-enforced braking system for chimeric antigen receptor (CAR) T-cell immunotherapy targeting TP53-mutant breast cancer. The research will be conducted at The Geneva Foundation's facility in Tacoma, Washington, and represents the...